Assembly Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASMB research report →
About the company
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV.
- CEO
- Jason A. Okazaki
- IPO
- 2010
- Employees
- 73
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $440.87M
- P/E
- -73.45
- P/S
- 6.20
- P/B
- 2.36
- EV/EBITDA
- -65.84
- Div Yield
- 0.00%
- Gross Margin
- 77.24%
- Op Margin
- -19.05%
- Net Margin
- -8.98%
- ROE
- -4.21%
- ROIC
- -6.74%
- Revenue
- $72.30M · 153.52%
- Net Income
- $-6,122,000 · 84.76%
- EPS
- $-0.55 · 91.78%
- Op Income
- $-12,118,000
- FCF YoY
- 19.52%
- 52W High
- $39.71
- 52W Low
- $16.90
- 50D MA
- $26.73
- 200D MA
- $29.04
- Beta
- 1.08
- Avg Volume
- 196.06K
Get TickerSpark's AI analysis on ASMB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Bjorkquist Jeanette M | sell | 29 |
| Mar 29, 26 | Gaggar Anuj | other | 14,000 |
| Mar 29, 26 | White Nicole S | other | 14,000 |
| Jun 4, 26 | McHutchison John G | other | 8,000 |
| Jun 4, 26 | Mahony Susan | other | 8,000 |
| Jun 4, 26 | Johnson-Pratt Lisa | other | 8,000 |
| Jun 4, 26 | Houghton Michael | other | 8,000 |
| Jun 4, 26 | Consylman Gina | other | 8,000 |
| Jun 4, 26 | ALTIG ANTHONY E | other | 8,000 |
| Mar 29, 26 | Bjorkquist Jeanette M | other | 3,500 |
Our ASMB coverage
Recent articles, reports, and earnings notes.
No research on ASMB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASMB report →Similar companies
Peers in the same neighborhood.